These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 34238283)

  • 1. Validation and minimum important difference of the UCSD Shortness of Breath Questionnaire in fibrotic interstitial lung disease.
    Chen T; Tsai APY; Hur SA; Wong AW; Sadatsafavi M; Fisher JH; Johannson KA; Assayag D; Morisset J; Shapera S; Khalil N; Fell CD; Manganas H; Cox G; To T; Gershon AS; Hambly N; Halayko AJ; Wilcox PG; Kolb M; Ryerson CJ
    Respir Res; 2021 Jul; 22(1):202. PubMed ID: 34238283
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Validation of a Dyspnea Visual Analog Scale in Fibrotic Interstitial Lung Disease.
    Bevanda L; Mok V; Lin K; Assayag D; Fisher JH; Johannson KA; Khalil N; Kolb M; Manganas H; Marcoux V; Sadatsafavi M; Wong AW; Ryerson CJ
    Ann Am Thorac Soc; 2024 Jul; 21(7):1007-1014. PubMed ID: 38315632
    [No Abstract]   [Full Text] [Related]  

  • 3. The UCSD shortness of breath questionnaire has longitudinal construct validity in idiopathic pulmonary fibrosis.
    Swigris JJ; Han M; Vij R; Noth I; Eisenstein EL; Anstrom KJ; Brown KK; Fairclough D
    Respir Med; 2012 Oct; 106(10):1447-55. PubMed ID: 22801586
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reliability, validity and responsiveness to change of the Saint George's Respiratory Questionnaire in early diffuse cutaneous systemic sclerosis.
    Wallace B; Kafaja S; Furst DE; Berrocal VJ; Merkel PA; Seibold JR; Mayes MD; Khanna D
    Rheumatology (Oxford); 2015 Aug; 54(8):1369-79. PubMed ID: 25667436
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Minimum important difference of the EQ-5D-5L and EQ-VAS in fibrotic interstitial lung disease.
    Tsai APY; Hur SA; Wong A; Safavi M; Assayag D; Johannson KA; Morisset J; Fell C; Fisher JH; Manganas H; Shapera S; Cox G; Gershon AS; Hambly N; Khalil N; To T; Wilcox PG; Halayko A; Kolb MR; Ryerson CJ
    Thorax; 2021 Jan; 76(1):37-43. PubMed ID: 33023996
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial.
    Maher TM; Corte TJ; Fischer A; Kreuter M; Lederer DJ; Molina-Molina M; Axmann J; Kirchgaessler KU; Samara K; Gilberg F; Cottin V
    Lancet Respir Med; 2020 Feb; 8(2):147-157. PubMed ID: 31578169
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Validity and Reliability of the Fatigue Severity Scale in a Real-World Interstitial Lung Disease Cohort.
    Aronson KI; Martin-Schwarze AM; Swigris JJ; Kolenic G; Krishnan JK; Podolanczuk AJ; Kaner RJ; Martinez FJ; Safford MM; Pinheiro LC;
    Am J Respir Crit Care Med; 2023 Jul; 208(2):188-195. PubMed ID: 37099412
    [No Abstract]   [Full Text] [Related]  

  • 8. Quality of life assessment in interstitial lung diseases:a comparison of the disease-specific K-BILD with the generic EQ-5D-5L.
    Szentes BL; Kreuter M; Bahmer T; Birring SS; Claussen M; Waelscher J; Leidl R; Schwarzkopf L
    Respir Res; 2018 May; 19(1):101. PubMed ID: 29801506
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A first look at the reliability, validity and responsiveness of L-PF-35 dyspnea domain scores in fibrotic hypersensitivity pneumonitis.
    Swigris JJ; Aronson K; Fernández Pérez ER
    BMC Pulm Med; 2024 Apr; 24(1):188. PubMed ID: 38641768
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Validation of the Brazilian Portuguese version of the University of California San Diego Shortness of Breath Questionnaire in patients with interstitial lung disease.
    Silva H; Mantoani LC; Zamboti CL; Aguiar WF; Ries AL; Gonçalves AFL; Silva TGD; Ribeiro M; Pitta F; Camillo CA
    J Bras Pneumol; 2021; 47(6):e20210172. PubMed ID: 34932719
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Frailty is common and strongly associated with dyspnoea severity in fibrotic interstitial lung disease.
    Milne KM; Kwan JM; Guler S; Winstone TA; Le A; Khalil N; Camp PG; Wilcox PG; Ryerson CJ
    Respirology; 2017 May; 22(4):728-734. PubMed ID: 27860036
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dyspnea assessment and pulmonary hypertension in patients with systemic sclerosis: utility of the University of California, San Diego, Shortness of Breath Questionnaire.
    Chung L; Chen H; Khanna D; Steen VD
    Arthritis Care Res (Hoboken); 2013 Mar; 65(3):454-63. PubMed ID: 23042670
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ambulatory oxygen in fibrotic lung disease (AmbOx): study protocol for a randomised controlled trial.
    Visca D; Tsipouri V; Mori L; Firouzi A; Fleming S; Farquhar M; Leung E; Maher TM; Cullinan P; Hopkinson N; Wells AU; Banya W; Whitty JA; Adamali H; Spencer LG; Sestini P; Renzoni EA
    Trials; 2017 Apr; 18(1):201. PubMed ID: 28454553
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Validation of the King's Brief Interstitial Lung Disease questionnaire in Idiopathic Pulmonary Fibrosis.
    Prior TS; Hilberg O; Shaker SB; Davidsen JR; Hoyer N; Birring SS; Bendstrup E
    BMC Pulm Med; 2019 Dec; 19(1):255. PubMed ID: 31856786
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Validation of the IPF-specific version of St. George's Respiratory Questionnaire.
    Prior TS; Hoyer N; Shaker SB; Davidsen JR; Yorke J; Hilberg O; Bendstrup E
    Respir Res; 2019 Aug; 20(1):199. PubMed ID: 31462235
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessing health-related quality of life in patients with interstitial lung diseases.
    Stoltefuß S; Leuschner G; Milger K; Kauke T; Götschke J; Veit T; Lenoir A; Kneidinger N; Behr J
    BMC Pulm Med; 2024 Sep; 24(1):452. PubMed ID: 39272068
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Health related quality of life in patients with idiopathic pulmonary fibrosis in clinical practice: insights-IPF registry.
    Kreuter M; Swigris J; Pittrow D; Geier S; Klotsche J; Prasse A; Wirtz H; Koschel D; Andreas S; Claussen M; Grohé C; Wilkens H; Hagmeyer L; Skowasch D; Meyer JF; Kirschner J; Gläser S; Herth FJF; Welte T; Neurohr C; Schwaiblmair M; Held M; Bahmer T; Frankenberger M; Behr J
    Respir Res; 2017 Jul; 18(1):139. PubMed ID: 28709421
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessing dyspnea and its impact on patients with connective tissue disease-related interstitial lung disease.
    Swigris JJ; Yorke J; Sprunger DB; Swearingen C; Pincus T; du Bois RM; Brown KK; Fischer A
    Respir Med; 2010 Sep; 104(9):1350-5. PubMed ID: 20471238
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Divergent perspectives: exploring the relationships between St. George's Respiratory Questionnaire and outcome measures in systemic sclerosis-associated interstitial lung disease.
    Basaran E; Temiz Karadag D; Cakir O; Gokcen N; Yazici A; Cefle A
    Clin Rheumatol; 2024 May; 43(5):1647-1656. PubMed ID: 38573479
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Depression and functional status are strongly associated with dyspnea in interstitial lung disease.
    Ryerson CJ; Berkeley J; Carrieri-Kohlman VL; Pantilat SZ; Landefeld CS; Collard HR
    Chest; 2011 Mar; 139(3):609-616. PubMed ID: 20688924
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.